Drugs / TB-500
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07487363 | Feb 2026 → Feb 2027 expected | atherosclerotic cardiovascular disease | Hudson Biotech | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TB-500 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07487363 ↗ |
| Known as | Thymosin Beta 4 17-23 Fragment | “A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled, Sequential Dose-Escalation Study of TB-500 (Thymosin Beta 4 17-23 Fragment) in Adults With Stable Atherosclerotic...” NCT07487363 ↗ |